{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(1)"],"submitter":["Desai J"],"funding":["BeiGene, Ltd."],"pubmed_abstract":["Background
The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used by cancer cells to evade the immune system. Tislelizumab, an investigational monoclonal antibody with high affinity and binding specificity for PD-1, was engineered to minimize binding to FcγR on macrophages to limit antibody-dependent phagocytosis, a potential mechanism of resistance to anti-PD-1 therapy. The aim of this phase IA/IB study was to investigate the safety/tolerability, antitumor effects and optimal dose and schedule of tislelizumab in patients with advanced solid tumors.Methods
Patients (aged ≥18 years) enrolled in phase IA received intravenous tislelizumab 0.5, 2, 5 or 10 mg/kg every 2 w"],"journal":["Journal for immunotherapy of cancer"],"pagination":["e000453"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7295442"],"repository":["biostudies-literature"],"pubmed_title":["Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors."],"pmcid":["PMC7295442"],"pubmed_authors":["Millward M","Sandhu S","Wu J","Lin CC","Rau KM","Desai J","Barlow P","Lee JS","Kang YK","Hill A","Chao Y","Paton V","Lu CH","Liang L","Markman B","Yen CJ","Horvath L","Wu CY","Deva S","Keam B","Jameson M","Friedlander M","Zhang Y","Hou MM","Lee KH"],"additional_accession":[]},"is_claimable":false,"name":"Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.","description":"Background
The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in suppressing antitumor immunity; axis dysregulation can be used by cancer cells to evade the immune system. Tislelizumab, an investigational monoclonal antibody with high affinity and binding specificity for PD-1, was engineered to minimize binding to FcγR on macrophages to limit antibody-dependent phagocytosis, a potential mechanism of resistance to anti-PD-1 therapy. The aim of this phase IA/IB study was to investigate the safety/tolerability, antitumor effects and optimal dose and schedule of tislelizumab in patients with advanced solid tumors.Methods
Patients (aged ≥18 years) enrolled in phase IA received intravenous tislelizumab 0.5, 2, 5 or 10 mg/kg every 2 w","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2026-06-15T06:07:23.234Z","creation":"2026-06-15T03:08:06.799Z"},"accession":"S-EPMC7295442","cross_references":{"pubmed":["32540858"],"doi":["10.1136/jitc-2019-000453"]}}